Literature DB >> 15223006

Molecular characterization of G6PD deficiency in Cyprus.

Anthi Drousiotou1, Elias H Touma, Nicoletta Andreou, Jacques Loiselet, Michalis Angastiniotis, Brian C Verrelli, Sarah A Tishkoff.   

Abstract

In the present study, we determined the frequency of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Cyprus using two different procedures in two separate adult population groups: a semiquantitative fluorescence test on blood spotted on filter paper and a quantitative spectrophotometric test on liquid blood. The frequency of G6PD deficiency among healthy adult males was found to be 5.1% using the semiquantitative procedure and 6.4% using the quantitative procedure. Neither method was able to detect all the expected female heterozygotes (5.3% and 47.1% of the expected number, respectively). A total of 21 male hemizygotes, 1 female homozygote and 9 female heterozygotes that tested positive for G6PD deficiency were studied at the molecular level. All 32 chromosomes were genotyped and five different mutations were identified. The Mediterranean mutation in exon 6 (563C-->T) (Ser188Phe) was found to be the most common variant in the Cypriot population, accounting for 52.6% of the deficient alleles. In the remaining chromosomes, four different mutations were identified: three known mutations, Kaiping 1388G-->A (Arg463His), Chatham 1003G-->A (Ala335Thr) and Acrokorinthos 463C-->G (His155Asp), and one previously undescribed mutation in exon 3, 148C-->T (Pro50Ser), which we called G6PD Kambos. We conclude that the frequency of G6PD deficiency in Cypriot males is 6.4%, and that this deficiency is the result of several different mutations. Although all the individuals carrying the Mediterranean variant can be detected using a semiquantitative screening method, a quantitative enzyme measurement is required to detect the G6PD variants with less severe enzyme deficiencies, while the most appropriate method for heterozygote detection is DNA analysis.

Entities:  

Mesh:

Year:  2004        PMID: 15223006     DOI: 10.1016/j.bcmd.2004.03.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  The prevalence of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T among G6PD deficient individuals from Western Iran.

Authors:  Hadi Mozafari; Zohreh Rahimi; Azadeh Heidarpour; Mahsa Fallahi; Adraiana Muniz
Journal:  Mol Biol Rep       Date:  2009-02-15       Impact factor: 2.316

2.  A novel point mutation in a class IV glucose-6-phosphate dehydrogenase variant (G6PD São Paulo) and polymorphic G6PD variants in São Paulo State, Brazil.

Authors:  Raimundo Antonio G Oliveira; Marilena Oshiro; Mario H Hirata; Rosario D C Hirata; Georgina S Ribeiro; Tereza M D Medeiros; Orlando C de O Barretto
Journal:  Genet Mol Biol       Date:  2009-06-01       Impact factor: 1.771

3.  Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia.

Authors:  Eugenia Lo; Daibin Zhong; Beka Raya; Kareen Pestana; Cristian Koepfli; Ming-Chieh Lee; Delenasaw Yewhalaw; Guiyun Yan
Journal:  Malar J       Date:  2019-10-07       Impact factor: 2.979

4.  A novel G6PD gene variant in a Chinese girl with favism.

Authors:  Shanshan Shen; Qian Xiong; Wenqian Cai; Hao Xiong; Xijiang Hu
Journal:  J Clin Lab Anal       Date:  2020-06-17       Impact factor: 2.352

5.  Molecular characterization of G6PD mutations reveals the high frequency of G6PD Aures in the Lao Theung population.

Authors:  Amkha Sanephonasa; Chalisa Louicharoen Cheepsunthorn; Naly Khaminsou; Onekham Savongsy; Issarang Nuchprayoon; Kamonlak Leecharoenkiat
Journal:  Malar J       Date:  2021-01-07       Impact factor: 2.979

6.  Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility.

Authors:  Marla K Johnson; Tamara D Clark; Denise Njama-Meya; Philip J Rosenthal; Sunil Parikh
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.